Hepatitis B Virus Treatment and Hepatocellular Carcinoma: Controversies and Approaches to Consensus

• Published in: Liver cancer (Basel ) Vol. 11; no. 6; pp. 497 - 510
• Main Authors: Kim, Soo Ki, Fujii, Takako, Kim, Soo Ryang, Nakai, Atsushi, Lim, Young-Suk, Hagiwara, Satoru, Kudo, Masatoshi
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 01.12.2022; Karger Publishers
• Subjects: alanine aminotransferase; Antiviral agents; Associations, institutions, etc; Biological products industry; Biological response modifiers; Clinical medicine; Clinical practice guidelines; Drug therapy; Health aspects; Hepatitis B; Hepatitis B virus; hepatocellular carcinoma; Hepatoma; immune-tolerant phase; Infections; Interferon; Liver; Liver cancer; Liver cirrhosis; Liver diseases; Medical research; Medicine, Experimental; Mortality; nucleos(t)ide analogs; Prevention; Review; Review Article; Societies; United States; East Asia; South Korea; Hepatocellular carcinoma; Alanine aminotransferase; Hepatitis B virus; Nucleos(t)ide analogs; Immune-tolerant phase
• ISSN: 2235-1795; 1664-5553
• DOI: 10.1159/000525518

Abstract Background: Long-term therapy with nucleos(t)ide analogs (NAs) such as entecavir (ETV) and tenofovir disoproxil fumarate (TDF) favorably affects the incidence of hepatocellular carcinoma (HCC) on the basis of data from randomized or matched control studies. Recent data suggest a lower HCC incidence after 5 years of ETV or TDF therapy in chronic hepatitis B (CHB) patients, especially those with baseline cirrhosis. Summary: Three controversial issues remain to be resolved regarding hepatitis B virus (HBV) treatment and HCC. (1) The efficacy of antiviral treatment for the prevention of HCC is not established. The guidelines of the American Association for the Study of Liver Diseases (AASLD), the Asian Pacific Association for the Study of the Liver (APASL), and the European Association for the Study of the Liver (EASL) for the management of HBV infection state that antiviral treatment of HBV with interferon and NAs prevents the development of HCC. Among experts in CHB treatment, however, there is disagreement on the HCC prevention effects of antiviral treatment. (2) The rationale for antiviral management in patients with high HBV DNA and normal levels of alanine aminotransferase is unclear. The AASLD, EASL, and APASL guidelines do not recommend antiviral treatment for immune-tolerant CHB patients, and the terms and methods of treating such patients remain to be clarified. (3) The efficacy of first-line treatment with NAs, including ETV, TDF, and tenofovir alafenamide fumarate (TAF), to prevent HCC in CHB patients remains unknown. Several studies have produced controversial results regarding the effects of NAs on the risk and prevention of HCC. In the present review, we discuss these 3 issues, citing recent studies and clinical management guidelines from major international associations. Key Messages: Suggested approaches for reaching a consensus including applying the propensity score matching method, performing randomized controlled studies, and performing clinical studies with larger numbers of subjects and longer follow-up.